Abstract: A specific, unique, natural biological factor that has the capacity to abate one or more of the toxic effects of TNF. This factor may have therapeutic potential in one or more of the diverse disease states in which TNF is known to have a causative role. The unique, approximately 27 kDa protein is designated TIP-B1. TIP-B1, when purified and added back to TNF sensitive cells, effectively ablates TNF-induced cell lysis and TNF-induced apoptosis; cytolytic effects are central to many TNF-mediated actions. The invention includes a protein designated TIP-B1 purified to homogeneity. The protein has a molecular weight of about 27 kD. The protein is capable of inhibiting the action of TNF upon a cell, when said protein is introduced into extracellular medium surrounding the cell. The protein is free of sequences which interfere with normal cellular TNF binding sites and is free of sequences which directly bind to TNF.

Abstract: A method for enhancing the therapeutic effectiveness of adriamycin, in the treatment of cancer, is disclosed. Liposomes containing coentrapped adriamycin and a secondary compound effective to reduce the toxicity of adriamycin or enhance the induction by adriamycin of the tumoricidal activity of host lymphoid cells, such as lipopolysaccharide, are administered parenterally in a therapeutically effective dose. In another aspect, macrophages stimulated in vivo with liposomes containing entrapped liposomes are exposed to an immunostimulator, for enhanced tumoricidal activity. Also disclosed are liposome compositions containing coentrapped adriamycin and an immunostimulator.